Core Insights - Galmed Pharmaceuticals is presenting a late-breaking abstract on its lead drug candidate, Aramchol, at the HEP-DART 2025 Meeting, highlighting its potential to enhance the efficacy of regorafenib in treating hepatocellular carcinoma (HCC) and other gastrointestinal (GI) cancers [2][3] Company Overview - Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing Aramchol for liver and cardiometabolic diseases, as well as GI oncological therapeutics [2][5] - The company aims to expand its product pipeline by exploring Aramchol's use in combination therapies, particularly for non-alcoholic steatohepatitis (NASH) and other oncological indications [5] Research and Development - The combination of Aramchol and regorafenib is based on findings that SCD1 inhibition enhances regorafenib's activity through ATM-AMPK-autophagy signaling, providing a scientific rationale for a Phase 1/2 clinical trial [2][3] - The planned clinical trial will begin enrollment in 2026, with a focus on advanced GI cancers, including HCC [3] Industry Context - HEP-DART serves as a platform for advancing knowledge in drug development for viral hepatitis and chronic liver diseases, aiming to address challenges in therapeutics for liver infections, diseases, and cancers [4]